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ORIGINAL ARTICLE
A 10-year study reveals clinical and laboratory
evidence for the ‘semi-invasive’ properties of chronic
pulmonary aspergillosis
Jasper Fuk-Woo Chan1,2,3,4, Susanna Kar-Pui Lau1,2,3,4, Sally Cheuk-Ying Wong2, Kelvin Kai-Wang To1,2,3,4,
Simon Yung-Chun So2, Sally Sau-Man Leung2, Siu-Mang Chan2, Chiu-Mei Pang2, Chenlu Xiao2,
Ivan Fan-Ngai Hung3,5, Vincent Chi-Chung Cheng2, Kwok-Yung Yuen1,2,3,4 and Patrick Chiu-Yat Woo1,2,3,4
In recent years, infections caused by Aspergillus sp. have become an emerging focus of clinical microbiology and infectious
disease, as the number of patients infected with Aspergillus sp. has increased markedly. Although chronic pulmonary aspergillosis
(CPA) is considered a ‘semi-invasive’ or ‘intermediate’ disease, little data are available for the direct comparison of CPA with
invasive pulmonary aspergillosis (IPA) and pulmonary aspergilloma (PA) to quantify invasiveness. In this study, we compared the
characteristics of CPA with those of IPA and PA among hospitalized patients over a 10-year period. A total of 29, 51 and 31 cases
of CPA, IPA and PA, respectively, were included. An increasing trend in galactomannan antigen seropositivity rate from PA (24.1%)
to CPA (35.7%) to IPA (54.9%) and an opposite trend for anti-Aspergillus antibody (PA (71.0%) to CPA (45.8%) to IPA (7.1%))
were observed. Eight percent of CPA patients were infected with more than one Aspergillus sp. The survival rate of the CPA group
also fell between the survival rate of PA and IPA, conﬁrming the intermediate severity of CPA. The survival rate of the CPA group
became signiﬁcantly higher than that of the IPA group from day 180 onwards until 2 years after admission (Po0.05). The survival
rate of the CPA group remained lower than that of the PA group from day 30 onwards until 2 years after admission. Poor prognostic
factors for CPA included older age (P=0.019), higher total leukocyte count (P=0.011) and higher neutrophil count (P=0.012) on
admission. This study provided clinical and laboratory evidence for the semi-invasive properties of CPA.
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INTRODUCTION
In recent years, infections caused by Aspergillus sp. have become an
emerging focus of clinical microbiology and infectious disease, as the
number of patients infected with Aspergillus sp. has increased
dramatically. Pulmonary aspergillosis is the most common form of
infection caused by Aspergillus sp. and is associated with signiﬁcant
morbidity and mortality in a wide range of susceptible hosts.1,2 Disease
evolvement after inhalation of Aspergillus spores is mainly determined
by the host’s systemic and local immune status. Two major non-
allergic forms of pulmonary aspergillosis were previously widely
recognized: simple pulmonary aspergilloma (PA), which is usually
an indolent disease that develops in patients with pre-existing lung
cavities, and invasive pulmonary aspergillosis (IPA), which mainly
occurs, in severely immunocompromised patients and is associated
with a nearly 100% mortality rate in the absence of prompt and
effective antifungal treatment.1 In the early 1980s, Gefter et al.3
and Binder et al.4 independently proposed a new clinical entity,
chronic necrotizing pulmonary aspergillosis, as an ‘intermediate’ or
‘semi-invasive’ form of pulmonary aspergillosis that occurs in patients
with chronic lung disease or mild immunosuppression. In 2003,
Denning et al.5 further proposed the additions of chronic cavitary
pulmonary aspergillosis and chronic ﬁbrosing pulmonary aspergillosis
to, and exclusion of simple PA from, the spectrum of chronic
pulmonary aspergillosis (CPA).
Over the past decade, CPA has been increasingly described in case
reports and small case series in different ethnic groups.1 A major
limitation of these published studies on CPA is the lack of objective
quantitation of its ‘semi-invasiveness’ by direct and systematic
comparison of the clinical and laboratory characteristics of CPA
with those of IPA and PA in patients from the same population over
a uniﬁed study period. This has made the accurate assessment of the
relative severities of these conditions problematic. Furthermore, the
comparative diagnostic performances of non-invasive serological tests,
including galactomannan antigen and antibody assays, which are
increasingly being used to diagnose the different forms of pulmonary
aspergillosis, have not been systemically compared. The positive rates
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of these non-invasive serological tests were variable in previous studies,
possibly due to inter-laboratory variations in methodology and result
interpretations. To objectively quantify the severity of CPA, we
conducted this 10-year retrospective cohort study to compare the
clinical, laboratory and prognostic characteristics of CPA with
those of IPA and PA in hospitalized patients from a single tertiary
referral center using tests uniformly performed by the same
laboratory. This study was the ﬁrst that systematically compared
the characteristics of hospitalized patients with CPA and those with
IPA and PA who were managed in the same institution using a
constant set of diagnostic criteria and mycological investigations
performed by a single laboratory. We objectively assessed the
relative severities based on microbiological investigation results and
clinical outcome, and we conﬁrmed CPA to be an intermediate
form of pulmonary aspergillosis.
MATERIALS AND METHODS
Patients and study design
This study was approved by the institutional review board of The
University of Hong Kong/Hospital Authority Hong Kong West
Cluster in Hong Kong. The electronic case records of hospitalized
patients diagnosed with ‘pulmonary aspergillosis’ at Queen Mary
Hospital, Hong Kong, between 1 July 2003 and 30 June 2013 were
retrieved and reviewed. The patients were categorized into three
groups according to the previously proposed diagnostic criteria
for CPA, IPA and PA (Table 1).5–8 For IPA, only patients with
proven, probable or probable IPA without prespeciﬁed radiologic
ﬁndings were included.6,7 Patients whose conditions did not fulﬁll
any of these diagnostic criteria were excluded. The epidemiological,
clinical, laboratory, radiological and mycological characteristics
were recorded into a predeﬁned database and were compared
and analyzed.
Table 1 Diagnostic criteria of pulmonary aspergilloma, chronic pulmonary aspergillosis and invasive pulmonary aspergillosis in this study
Category Diagnostic criteria
Chronic pulmonary aspergillosisa All of the following:
1. Chronic pulmonary or systemic symptoms (duration, three months) compatible with chronic pulmonary aspergillosis, including
at least one of the following symptoms: weight loss, productive cough or hemoptysis.
2. Cavitary pulmonary lesion with evidence of paracavitary inﬁltrates, new cavity formation or expansion of cavity size over time.
3. Either positive result of serum Aspergillus precipitins test or isolation of Aspergillus sp. from pulmonary or pleural cavity.
4. Elevated levels of inﬂammatory markers (C-reactive protein, plasma viscosity or erythrocyte sedimentation rate).
5. Exclusion of other pulmonary pathogens, by results of appropriate cultures and serological tests, that are associated with similar
disease presentation, including mycobacteria and endemic fungi (especially Coccidioides immitis and Histoplasma capsulatum).
6. No overt immunocompromising conditions (for example, HIV infection, leukemia and chronic granulomatous disease).
Invasive pulmonary aspergillosisb
Proven Microscopic analysis (sterile material): histologic, cytologic or direct microscopic examination of a specimen obtained by needle
aspiration or biopsy in which hyphae are seen accompanied by evidence of associated tissue damage.
Culture (sterile material): recovery of Aspergillus sp. by culture of a specimen obtained by a sterile procedure from a normally
sterile and clinically or radiologically abnormal site consistent with an infectious disease process, excluding bronchoalveolar lavage
ﬂuid.
Probable Host factors (any one):
1. Recent history of neutropenia (o0.5x109 neutrophils/L for 4ten days) temporally related to the onset of fungal disease.
2. Receipt of an allogeneic stem cell transplant.
3. Prolonged use of corticosteroids at a mean minimum dose of 3 mg/kg/day of prednisone equivalent for 4three weeks.
4. Treatment with other recognized T-cell immunosuppressants, such as cyclosporine, TNF-α blockers, speciﬁc monoclonal
antibodies (such as alemtuzumab) or nucleoside analogues during the past 90 days.
5. Inherited severe immunodeﬁciency (such as chronic granulomatous disease or severe combined immunodeﬁciency).
Clinical criteria:
The presence of one of the following three signs on CT: (1) dense, well-circumscribed lesion(s) with or without a halo sign; (2) air-
crescent sign; or cavity.
Mycological criteria (any one):
1. Direct test (cytology, direct microscopy, or culture): Aspergillus sp. in sputum, tracheal aspirate, bronchoalveolar lavage ﬂuid,
bronchial brush, indicated by either the presence of fungal elements denoting a mold or recovery by culture of Aspergillus sp.
2. Indirect tests (detection of antigen or cell–wall constituents): galactomannan antigen detected in plasma or serum.
Probable without prespeciﬁed
radiologic ﬁndings
Same as for ‘probable’ invasive pulmonary aspergillosis except that a positive serum galactomannan antigen result was required,
and the abnormal pulmonary inﬁltrates ﬁndings did not fulﬁll the prespeciﬁed radiological criteria.
Pulmonary aspergillomac The presence of a single mobile mass within an existing cavity on chest radiograph or thoracic CT scan, with or without culture of
Aspergillus sp. from respiratory tract specimens.
Abbreviations: computerized tomography, CT; human immunodeﬁciency virus, HIV.
aAdopted from Denning et al.5
bAdopted from De Pauw et al.6 and Nucci et al.7 Possible IPA was not included in this study.
cAdopted from Tam et al.8
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Setting
Queen Mary Hospital, a 1600-bed institution, is the afﬁliated
teaching hospital of The University of Hong Kong, which offers
tertiary referral services, including hematopoietic stem cell and
solid organ transplantation, cardiopulmonology and intensive care,
as well as emergency services for internal medicine, surgery,
pediatrics, and obstetrics and gynecology. The patients in this
study were not managed in airborne infection isolation rooms
unless otherwise speciﬁed.
Mycological investigations
Detection of serum galactomannan antigen and anti-Aspergillus anti-
body was performed using the Platelia Aspergillus Ag enzyme
immunoassay (Bio-Rad Laboratories, Redmond, WA, USA) and the
Meridian Bioscience Fungal Immunodiffusion System (Meridian
Bioscience Inc., Cincinnati, OH, USA), respectively, according to the
manufacturers’ instructions. An index value of ⩾ 0.5 was considered
positive for the serum galactomannan antigen assay. Fungal culture
of respiratory tract specimens was performed as previously described.9
Brieﬂy, the specimens were processed within 24 h upon their arrival at
the clinical microbiology laboratory, and all of the procedures were
performed inside a class II biosafety cabinet to avoid possible culture
contamination. The specimens were concentrated by centrifugation
for 10 min at 2000 rcf, and the pellet was then resuspended in 1 mL of
0.85% NaCl. A heavy inoculum (~0.25–0.5 mL) was then inoculated
onto Sabouraud dextrose agar (Sigma-Aldrich, St Louis, MO, USA)
supplemented with chloramphenicol (50 μg/mL), and the plate was
then incubated at 30 °C until moldy colonies were observed at the
primary inoculation sites.
Statistical analysis
All statistical analyses were performed using PASW Statistics
software (version 18.0.0). The Fisher’s exact and chi-square
tests were used for categorical variables where appropriate, and
the Mann–Whitney U-test was used for continuous variables. The
log-rank test was used to compare survival distributions. To
determine whether a parameter was independently associated with
death, backward stepwise multivariate regression analysis was used
to control for confounding clinical risk conditions. P-valueso0.05
were considered statistically signiﬁcant.
RESULTS
Patients
A total of 167 patients were diagnosed with ‘pulmonary
aspergillosis’ in the 10-year study period (Figure 1). Fifty-six
patients did not fulﬁll the diagnostic criteria and were excluded,
and a total of 29, 51 and 31 patients fulﬁlled the diagnostic criteria
of CPA, IPA and PA, respectively. The demographic characteristics
of the patients and their laboratory investigation results are
described in Table 2. The median age of the CPA group (64 years)
was signiﬁcantly higher than the IPA group (51 years), but was not
signiﬁcantly different from the PA group. The male to female ratio
did not signiﬁcantly differ between the CPA group and either the
IPA group or the PA group. As expected from the case deﬁnitions,
a higher proportion of the IPA group had systemic immunocom-
promising conditions, such as neutropenia, hematopoietic stem
cell or solid organ transplantation, malignancy, and recent che-
motherapy or immunosuppressant exposure, whereas higher pro-
portions of the CPA and PA groups had chronic lung diseases or
past pulmonary tuberculosis (Supplementary Table S1).
Mycological investigations
An increasing trend in the galactomannan antigen seropositivity rate
from PA (24.1%) to CPA (35.7%) to IPA (54.9%) and an opposite
trend for anti-Aspergillus antibody PA (71.0%) to CPA (45.8%) to IPA
(7.1%) were observed (Table 2). The respiratory tract specimen
cultures (CPA, 86.2%; IPA, 63.6%; PA, 64.5%) did not differ
signiﬁcantly between the CPA group and either the IPA group or
the PA group. Aspergillus fumigatus was the most commonly isolated
species in all three groups (CPA, 68.0%; IPA, 64.3%; PA, 50.0%).
Nearly one-tenth of the culture-positive CPA patients had more than
one species isolated from the respiratory tract specimens, whereas
none of the culture-positive IPA and PA patients had more than one
Aspergillus species isolated from the respiratory tract specimens.
Radiological ﬁndings
As expected from the case deﬁnitions, PA patients had a unilobar
lesion involving either the upper lobe as viewed in a chest X-ray
(CXR) and thoracic computed tomography (CT) scan, whereas
over 40% of CPA and IPA patients had lesions in more than one
lobe in CXR and thoracic CT scan (Table 3). Most CPA and IPA
patients with multilobar lesions had bilateral upper lobe involve-
ment, whereas involvement of the other lobes was less common.
Cavitary lesion and consolidation and/or collapse were the most
common ﬁndings in both CXR and thoracic CT scan in CPA
and IPA patients, respectively. Only around one-third of the IPA
group had the classical ﬁndings of cavitary lesion, halo and/or
air-crescent signs. Fibrosis was also more commonly found in the
CPA group in both CXR and thoracic CT scan. CXR was much less
sensitive than thoracic CT scan in detecting cavitary lesions in
both groups because of coexisting radiological abnormalities,
including consolidation, collapse and/or ﬁbrosis. Thoracic CT scan
also detected more abnormalities, including consolidation, col-
lapse, nodules, pleural effusion and ﬁbrosis, in both groups.
However, the rarity of consolidation and collapse allowed CXR
to be as sensitive as thoracic CT scan in detecting cavitary lesions in
the PA group, whereas over one-third of the cavitary lesions were
undetected in CXR in the CPA group.
Treatment outcome and prognostic factors
A signiﬁcantly higher proportion of the CPA group (100.0%) than the
IPA (80.4%) and PA (48.4%) groups received antifungal drugs with
anti-aspergillus activity, including itraconazole, voriconazole, posaco-
nazole, caspofungin, micafungin, anidulafungin and/or amphotericin
B (Table 2). Nearly 20% of the IPA group did not receive any
antifungal treatment before death. The duration of antifungal treat-
ment was longer in the CPA group (median, 176.5 days) than the IPA
(median, 42.5 days) and PA (median, 106.0 days) groups, although the
difference did not reach statistical signiﬁcance. None of the PA or CPA
patients received surgical resection of an aspergilloma. The duration of
hospitalization was signiﬁcantly shorter in the CPA group (median,
19.0 days) than the IPA group (median, 38.0 days). The survival rates
of the CPA group at 30 days, 60 days, 90 days, 180 days, one year, and
two years after admission were 89.7%, 86.2%, 82.8%, 79.3%, 75.9%
and 72.4%, respectively (Figure 2). The survival rate of the CPA group
became signiﬁcantly higher than that of the IPA group from day 180
(CPA, 79.3%; IPA, 54.9%; P= 0.033) onwards until two years after
admission (CPA, 72.4%; IPA, 43.1%; P= 0.019; Figure 2). The survival
rate of the CPA group consistently remained lower than that of the PA
group from day 30 (CPA, 89.7%; PA, 100.0%; P= 0.107) onwards
until 2 years (CPA, 72.4%; PA, 77.4%; P= 0.769) after admission,
although the difference was not signiﬁcantly different (Figure 2). The
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Figure 1 The total number of patients with CPA, IPA and PA, and the reasons for exclusion are shown. chronic pulmonary aspergillosis, CPA; invasive
pulmonary aspergillosis, IPA; pulmonary aspergilloma, PA.
Table 2 Comparative demographics, mycological investigation results, hospitalization and treatment of patients with chronic pulmonary
aspergillosis, invasive pulmonary aspergillosis and pulmonary aspergilloma
Parameter CPA (n=29) IPA (n=51) P (CPA versus IPA) PA (n=31) P (CPA versus PA)
Age (years) 64 (7–83) 51 (7–82) o0.001 66 (40–87) NS
Sex (male) 25 (86.2) 34 (66.7) NS 28 (90.3) NS
Mycological investigations
Serum galactomannan antigena 10 (35.7) 28 (54.9) NS 7 (24.1) NS
Serum anti-Aspergillus antibodyb 11 (45.8) 3 (7.1) o0.001 22 (71.0) NS
Culture
Positive culture from any respiratory tract specimenc 25 (86.2) 28 (63.6) NS 20 (64.5) NS
Aspergillus species isolated from culture
Aspergillus fumigatus 17 (68.0) 18 (64.3) NS 10 (50.0) NS
Aspergillus ﬂavus 2 (8.0) 3 (10.7) NS 0 (0.0) NS
Aspergillus niger 0 (0.0) 0 (0.0) NS 3 (15.0) NS
Aspergillus terreus 0 (0.0) 1 (3.6) NS 1 (5.0) NS
Aspergillus sp. 4 (16.0) 6 (21.4) NS 6 (30.0) NS
41 species 2 (8.0) 0 (0.0) NS 0 (0.0) NS
Duration of hospitalization (days) 19.0 (1.0–150.0) 38.0 (1.0–177.0) 0.031 12.0 (1.0–137.0) NS
Antifungal treatment
Use of antifungal drugs 29 (100.0) 41 (80.4) 0.011 15 (48.4) o0.001
Itraconazole 25 17 o0.001 13 o0.001
Voriconazole 10 19 NS 3 0.028
Posaconazole 0 4 NS 0 NS
Amphotericin B 2 17 0.012 0 NS
Echinocandins 0 15 0.002 1 NS
Duration of antifungal drugs (days) 176.5 (8.0–539.0) 42.5 (1.0–502.0) NS 106.0 (7.0–411.0) NS
Abbreviations: bronchoalveolar lavage, BAL; chronic pulmonary aspergillosis, CPA; computerized tomography, CT; chest radiograph, CXR; invasive pulmonary aspergillosis, IPA; left lower lobe, LLL;
left upper lobe, LUL; not signiﬁcant, NS; pulmonary aspergilloma, PA; right lower lobe, RLL; right middle lobe, RML; right upper lobe, RUL.
The data are the number or proportion (%) of patients.
aSerum galactomannan antigen was obtained in 28 (96.6%), 51 (100.0%) and 29 (93.5%) patients with CPA, IPA and PA, respectively.
bSerum anti-Aspergillus antibody was obtained in 24 (82.8%), 42 (82.4%) and 31 (100.0%) patients with CPA, IPA and PA, respectively.
cAt least one respiratory tract specimen was collected for fungal culture in 29 (100.0%), 44 (86.3%) and 31 (100.0%) patients with CPA, IPA and PA, respectively.
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survival rate of CPA (5/8, 62.5%) patients who died from the infection
was also intermediate between those who died of PA (1/7, 14.3%) and
IPA (22/29, 75.9%). On analysis of the prognostic indicators,
subgroup univariate analysis showed that patients who died from
CPA within two years after admission were signiﬁcantly older
(69.0± 7.1 versus 60.5± 17.8 years; P= 0.019) and had higher total
leukocyte (9.3± 5.3 versus 6.2± 3.7; P= 0.011) and neutrophil counts
(7.7± 5.1 versus 4.6± 3.9; P= 0.012) on admission than those who
survived. Other laboratory parameters, including lymphocyte and
platelet counts, serum levels of sodium, potassium, urea, creatinine,
albumin, globulin, bilirubin, alkaline phosphatase, alanine transferase,
aspartate transferase and random glucose, and the duration of
antifungal treatment and hospitalization, were not signiﬁcantly differ-
ent between the death and survival CPA groups. Multivariate analysis
showed that a higher total leukocyte count was the only independent
prognostic factor (odds ratio= 1.230; 95% conﬁdence interval=
1.014–1.493; P= 0.036).
DISCUSSION
CPA has long been described as an ‘intermediate’ or ‘semi-invasive’
form of pulmonary aspergillosis.3–5 However, direct comparison of
CPA with IPA and PA using results from previous studies that
separately assessed these entities was limited by their heterogeneous
patient populations, study periods, and laboratory test methods and
result interpretations. This 10-year retrospective study was the ﬁrst to
systematically compare the characteristics of hospitalized patients with
CPA and those with IPA and PA who were managed in the same
institution using a constant set of diagnostic criteria and mycological
investigations performed by a single laboratory. We showed that the
overall characteristics of CPA more closely resembled those of PA than
IPA, and we made novel observations with important implications on
Table 3 Comparative radiological investigation results of patients with chronic pulmonary aspergillosis, invasive pulmonary aspergillosis and
pulmonary aspergilloma
Investigation CPA (n=29) IPA (n=51) P (CPA versus IPA) PA (n=31) P (CPA versus PA)
Radiological studiesa
Site of CXR abnormality
RUL 7 (24.1) 5 (9.8) NS 16 (51.6) 0.036
RML 3 (10.3) 4 (7.8) NS 0 (0.0) NS
RLL 1 (3.4) 3 (5.9) NS 1 (3.2) NS
LUL 5 (17.2) 5 (9.8) NS 14 (45.2) 0.027
LLL 0 (0.0) 1 (2.0) NS 0 (0.0) NS
Multilobar 13 (44.8) 30 (58.8) NS 0 (0.0) o0.001
CXR features
Normal 0 (0.0) 3 (5.9) NS 0 (0.0) NS
Cavitary lesion(s) 19 (65.5) 8 (15.7) o0.001 31 (100.0) o0.001
Consolidation or collapse 10 (34.5) 31 (60.8) 0.036 2 (6.5) 0.009
Nodule(s) 2 (6.9) 8 (15.7) NS 5 (16.1) NS
Pleural effusion 2 (6.9) 9 (17.6) NS 0 (0) NS
Fibrosis 13 (44.8) 7 (13.7) o0.001 19 (61.3) NS
Site of thoracic CT scan abnormality
RUL 4 (15.4) 3 (9.4) NS 16 (53.3) 0.005
RML 3 (11.5) 2 (6.3) NS 0 (0.0) NS
RLL 1 (3.8) 0 (0.0) NS 0 (0.0) NS
LUL 5 (19.2) 3 (9.4) NS 14 (46.7) 0.047
LLL 0 (0.0) 1 (3.1) NS 0 (0.0) NS
Multilobar 13 (50.0) 22 (68.8) NS 0 (0.0) o0.001
Thoracic CT scan features
Normal 0 (0.0) 1 (3.1) NS 0 (0.0) NS
Cavitary lesion(s), halo or air-crescent sign 26 (100.0) 12 (37.5) o0.001 30 (100.0) NS
Consolidation or collapse 12 (46.2) 14 (43.8) NS 2 (6.7) 0.002
Nodule(s) 6 (23.1) 13 (40.6) NS 8 (26.7) NS
Pleural effusion 4 (15.4) 8 (25.0) NS 2 (6.7) NS
Fibrosis 14 (53.8) 6 (18.8) o0.001 23 (76.7) NS
Abbreviations: bronchoalveolar lavage, BAL; chronic pulmonary aspergillosis, CPA; computerized tomography, CT; chest radiograph, CXR; invasive pulmonary aspergillosis, IPA; left lower lobe, LLL;
left upper lobe, LUL; not signiﬁcant, NS; pulmonary aspergilloma, PA; right lower lobe, RLL; right middle lobe, RML; right upper lobe, RUL.
The data are the number or proportion (%) of patients.
aCXR was performed in all 111 patients. Thoracic CT scan was performed in 26 (89.7%), 30 (96.7%) and 32 (62.7%) patients with CPA, PA and IPA, respectively.
Figure 2 Kaplan–Meier survival curves for CPA, IPA and PA through two
years after admission are shown. The values in percentage represent survival
rates at 2 years after admission. CPA, chronic pulmonary aspergillosis; IPA,
invasive pulmonary aspergillosis; PA, pulmonary aspergilloma.
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the distinction of CPA from IPA and PA, and the assessment of their
relative severities based on clinical outcome.
Although a number of novel diagnostic tests have been developed
for pulmonary aspergillosis, serum galactomannan antigen and anti-
Aspergillus antibody remain the most widely used non-invasive tests
in most laboratories.10–15 We observed several important phenomena
when comparing the performance of serum galactomannan antigen,
serum anti-Aspergillus antibody, and culture of respiratory tract
specimens among the three groups. Firstly, an increasing trend
in the seropositive rate of galactomannan antigen from PA (24.1%)
to CPA (35.7%) to IPA (54.9%) and an opposite trend for anti-
Aspergillus antibody (PA, 71.0%; CPA, 45.8%; IPA, 7.1%) were noted
(Table 2). The rates correlated with the degree of host immunosup-
pression and the invasiveness of the infection in the three groups,
and supported the long-standing dogma that CPA represents an
intermediate form of pulmonary aspergillosis that lies between the
indolent PA and the aggressive IPA. Second, serum galactomannan
antigen did not reliably differentiate CPA from IPA and PA, and
should not be used to differentiate CPA from IPA or PA. However,
serum anti-Aspergillus antibody was much more likely to be positive
in CPA and PA than in IPA and might be useful in cases where
the diagnosis is uncertain. For example, the serum anti-Aspergillus
antibody test may be useful for overlap syndromes in which more than
one form of pulmonary aspergillosis coexists in the same patient and
in cases of misdiagnosis of IPA as CPA in patients without classical
risk factors, especially critically ill patients in the intensive care unit
and patients with chronic obstructive pulmonary disease.1,6,16,17 Third,
although A. fumigatus was consistently the most commonly isolated
species in all three groups,41 species were found in 8.0% of patients
with CPA while none with IPA and PA had a mixed infection.
This ﬁnding might affect the choice of antifungal treatment and
highlighted the importance of performing antifungal susceptibility
tests, especially in CPA patients who do not respond well to ﬁrst-line
treatment. Finally, we observed a lower seropositive rate of anti-
Aspergillus antibody in our CPA group than reported in previous
studies (45.8% versus ⩾ 70%).5,7 The apparent difference might be
due to various reasons, including the timing of disease as the titer of
serum antibody may vary over time or even revert to negative in CPA,
the ﬁbrosing form of CPA as IgG serological response may be negative
in such patients, and the inclusion of immunocompromised patients
who failed to elicit an adequate antibody response.5
Similar to previous reports on the radiological appearances
of pulmonary aspergillosis, characteristic cavitary lesions were
predominantly found in the upper lobes in all three groups in our
cohort. However, these lesions were missed in the CXR of more than
one-third of the CPA group and one-half of the IPA group, as many
had coexisting consolidation, collapse and/or ﬁbrosis. Our ﬁndings
supported the use of thoracic CT scan in patients with suspected
CPA or IPA but not patients with PA with whom CXR and thoracic CT
scan were equally sensitive for detecting cavitary lesions. CPA
could be differentiated from PA radiologically, as the former
frequently appeared as multilobar involvement with various radiological
ﬁndings not limited to cavitary lesions alone, whereas the latter usually
manifested as a unilobar upper lobe cavitary lesion with or without
coexisting ﬁbrosis from previous lung damage. CPA might be differ-
entiated from IPA by the presence of pulmonary ﬁbrosis associated with
their underlying chronic lung diseases and/or the ﬁbrosing form of CPA.
The clinical outcome of our patients also supported the inter-
mediate severity of CPA (Figure 2). The survival rate of the CPA group
remained consistently intermediate between the IPA and PA groups
from day 30 up to two years after admission. The survival rate of
the CPA group became signiﬁcantly higher than that of the IPA
group from day 180 onwards until two years after admission
(Po0.05). The prognostic indicators identiﬁed in subgroup univariate
analysis (older age and higher total leukocyte and neutrophil counts
on admission among those who died than those who survived) and
multivariate analysis (higher total leukocyte count) suggested that
inadequate control of pulmonary inﬂammation in immunosenescent
hosts was essential in determining the outcome of CPA but not in the
prognosis of IPA or PA by either univariate or multivariate analysis.
Patients with CPA were the most likely among the three groups to
receive antifungal treatment (CPA, 100.0%; IPA, 80.4%; PA, 48.4%),
and the median treatment duration was also the longest (CPA,
176.5 days; IPA, 42.5 days; PA, 106.0 days), corroborating the slowly
progressive course of CPA, which might improve with long-term
antifungal treatment (Table 1).18 In contrast, nearly 20% of the
patients with the more invasive IPA died before the diagnosis was
suspected or shortly after treatment was started, and the less-invasive
PA usually did not warrant treatment. In those who survived in the
CPA group, a much shorter hospitalization duration for rehabilitation
was usually required when compared with those who survived in the
IPA group. A signiﬁcantly higher proportion of CPA patients than IPA
and PA patients received itraconazole. This was likely related to the
availability and lower cost of the oral preparation of itraconazole.
However, amphotericin B and echinocandins were more commonly
used among IPA patients, as these drugs required intravenous
administration and were more expensive and were reserved for the
IPA patients with more severe infections.
Our study had several limitations. First, our study was subject to the
intrinsic limitations of retrospective analyses. Nevertheless, this was
the ﬁrst and largest cohort for the systemic comparison of the three
major non-allergic forms of pulmonary aspergillosis that provided
novel, clinically relevant observations. Second, in contrast to the
reported incidence of pulmonary aspergillosis, there were relatively
fewer cases of PA, as we only included hospitalized patients to increase
the homogeneity of the cohort. As our PA group had characteristics
similar to those reported in other studies, we considered them to be
representative of PA in general. Third, we did not evaluate
the signiﬁcance of the serum galactomannan antigen index value, as
some of the data were not retrievable. Fourth, the sensitivity of the
anti-Aspergillus antibody assay used in our study may be suboptimal to
other newer assays. However, as this 10-year study data were retro-
spectively collected, we were unable to retest the serum samples with
an additional antibody test. Finally, the number of diagnostic tests
performed was not uniform in each patient. More opportunities
were available for repeated testing in the slowly progressing CPA and
PA patients than the rapidly progressing IPA patients. However, we
consider our study to be clinically relevant, as the data represent real-
life scenarios encountered by clinicians in the diagnosis and manage-
ment of pulmonary aspergillosis over a long study period.
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